Ruxolitinib

• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended
  2023-506139-13-00 Phase III 13 countries Karyopharm Therapeutics Inc.
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended
  2023-503952-28-00 Phase II 5 countries Medac Gesellschaft fuer klinische Spezialprapaerate mbH
• A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended
  2023-507468-38-00 Phase II 3 countries Takeda Development Center Americas Inc.
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi… Ended
  2023-509635-89-00 Phase I/II 7 countries Bristol-Myers Squibb Services Unlimited Company
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit… Ended
  2023-507274-40-00 Phase I (Other) 6 countries AbbVie Deutschland GmbH & Co. KG
• Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M… Ended
  2024-514468-26-00 Phase I/II 2 countries Kartos Therapeutics Inc.
• PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended
  2024-515953-52-00 Phase III 8 countries Sobi Inc.
• A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab… Ended
  2024-520123-83-01 Phase II 1 country Universita' Degli Studi Di Perugia
• An open label, multi-center, Phase IV rollover protocol to evaluate long term safety data Ended
  2024-515283-31-00 Phase IV 4 countries Novartis Pharma Services AG
• Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA… Ended
  2024-515619-23-00 Phase II 1 country Universitaetsklinikum Aachen AöR
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera… Ended
  2023-505433-27-00 Phase III 9 countries Incyte Corp.
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 Phase III 8 countries Incyte Corp.
• An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo Ended
  2023-503737-22-00 Phase II 1 country Incyte Corp.
• A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label E… Ended
  2022-502827-23-00 Phase II 2 countries Incyte Corp.
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 Phase III 7 countries Incyte Corp.
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi… Ended
  2023-507276-53-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended
  2024-511972-33-00 Phase III 10 countries Celgene Corp.

Showing 25–41 of 41 trials